HC Wainwright Expects Higher Earnings for Avalo Therapeutics

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of Avalo Therapeutics in a research report issued to clients and investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.43) for the year, up from their prior forecast of ($2.76). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2026 earnings at ($0.55) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.55) EPS, Q3 2027 earnings at ($0.56) EPS, Q4 2027 earnings at ($0.57) EPS and FY2027 earnings at ($2.23) EPS.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.25.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research note on Wednesday, September 16th. BTIG Research dropped their price target on shares of Avalo Therapeutics to $10.00 and set a “buy” rating on the stock in a research note on Friday, October 23rd. Oppenheimer set a $16.00 price target on shares of Avalo Therapeutics in a report on Monday, October 26th. Finally, Guggenheim lowered shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, October 23rd. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.82.

Avalo Therapeutics Stock Performance

NASDAQ:AVTX opened at $7.27 on Tuesday. The stock’s 50 day moving average price is $13.24 and its 200 day moving average price is $15.80. Avalo Therapeutics has a 52 week low of $6.53 and a 52 week high of $24.27.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total transaction of $202,394.02. Following the transaction, the chief financial officer owned 39,900 shares of the company’s stock, valued at approximately $651,567. This represents a 23.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 23,258 shares of company stock worth $395,434. Corporate insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Avalo Therapeutics

Large investors have recently added to or reduced their stakes in the stock. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics during the first quarter worth approximately $174,000. Glenmede Trust Co. NA grew its holdings in Avalo Therapeutics by 25.8% during the first quarter. Glenmede Trust Co. NA now owns 25,730 shares of the company’s stock valued at $384,000 after purchasing an additional 5,280 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics in the first quarter valued at approximately $607,000. Sei Investments Co. bought a new position in shares of Avalo Therapeutics in the first quarter valued at approximately $849,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Avalo Therapeutics in the second quarter valued at approximately $1,897,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.